Clinicopathologic features and outcome of young adults with stage IV colorectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 6, 2015, Pages 543-549

  Hawk, Natalyn N ^a   Long, Tua Elisabeth ^b   Imam, Muhammad H ^b   Mathew, Blessy M ^b   Kim, Sungjin ^a   Chen, Zhengjia ^a   Goodman, Michael ^a,b   Sullivan, Patrick ^b   Brutcher, Edith ^a   Kauh, John ^a   Maithel, Shishir K ^b   Adsay, Volkan N ^a   Farris, Alton B ^a   Staley, Charles ^b   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Chemotherapy; Clinicopathologic features; Demographics; Histology; Mucinous histology; Prognostic features; SEER analysis; Signet ring cell histology; Stage IV colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; ETHNICITY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; ADENOCARCINOMA; CAUCASIAN; COLLOID CARCINOMA; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; SIGNET RING CARCINOMA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AFRICAN AMERICANS; AGE FACTORS; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEER PROGRAM; SEX FACTORS; TREATMENT OUTCOME;

EID: 84948583583     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000437899.28701.03     Document Type: Article

References (67)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Ries LAG, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000; 88: 2398-2424.
3. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375: 1624-1633.
4. O'Connell JB, Maggard MA, Liu JH, et al. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003; 69: 866-872.
5. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008; 8: 288-298.
6. Tricoli JV, Seibel NL, Blair DG, et al. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst. 2011; 103: 628-635.
7. Derwinger K, Kodeda K, Gerjy R. Age aspects of demography, pathology and survival assessment in colorectal cancer. Anticancer Res. 2010; 30: 5227-5232.
8. Fairley TL, Cardinez CJ, Martin J, et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer. 2006; 107: 1153-1161.
9. Leff DR, Chen A, Roberts D, et al. Colorectal cancer in the young patient. Am Surg. 2007; 73: 42-47.
10. Peltomäki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 1993; 53: 5853-5855.
11. Urso E, Pucciarelli S, Agostini M, et al. Proximal colon cancer in patients aged 51-60 years of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines. Int J Colorectal Dis. 2008; 23: 801-806.
12. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003; 348: 919-932.
13. Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000; 342: 137-138.
14. Schellerer VS, Hohenberger W, Croner RS. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg. 2012; 214: 2-2.
15. Chang DT, Pai RK, Rybicki LA, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012; 25: 1128-1139.
16. Zbuk K, Sidebotham EL, Bleyer A, et al. Colorectal cancer in young adults. Semin Oncol. 2009; 36: 439-450.
17. Al-Jaberi TM, Yaghan RJ, El-Heis HA. Colorectal cancer in young patients under 40 years of age. Comparison with old patients in a well defined Jordanian population. Saudi Med J. 2003; 24: 871-874.
18. Schellerer V, Merkel S, Schumann S, et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer. Int J Colorectal Dis. 2012; 27: 71-79.
19. Chung YFA, Eu KW, Machin D, et al. Young age is not a poor prognostic marker in colorectal cancer. Br J Surg. 1998; 85: 1255-1259.
20. O'Connell JB, Maggard MA, Liu JH, et al. Do young colon cancer patients have worse outcomes? World J Surg. 2004; 28: 558-562.
21. Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol. 2011; 29: 2781-2786.
22. You YN, Dozois E, Boardman L, et al. Young-onset rectal cancer: presentation, pattern of care and long-term oncologic outcomes compared to a matched older-onset cohort. Ann Surg Oncol. 2011; 18: 2469-2476.
23. Chiang JM, Chen MC, Changchien CR, et al. Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis Colon Rectum. 2003; 46: 904-910.
24. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008; 26: 689-690.
25. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004; 5: 2159-2170.
26. Edwards MS, Chadda SD, Zhao Z, et al. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012; 14: e31-e47.
27. Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet. 2013; 381: 303-312.
28. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30: 3499-3506.
29. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22: 1209-1214.
30. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237.
31. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-2019.
32. Institute NC: National Cancer Institute. SEER as a Research Resource. Bethesda, MD: NIH Publication; 2010.
33. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons; 1980.
34. Cox D. Regression models and life tables. J R Stat Soc. 1972; B34: 187-220.
35. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351.
36. Team RDC. R: A Language and Environment for Statistical Computing, Reference Index Version 2.14.1. Vienna: R Foundation for Statistical Computing; 2011.
37. Joinpoint regression program, (ed 3.5). Statistical Methodology and Applications Branch and Data Modeling Branch. Bethesda, Maryland: Surveillance Research Program National Cancer Institute; 2011.
38. Laiyemo AO, Doubeni C, Pinsky PF, et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010; 102: 538-546.
39. Demissie K, Oluwole OO, Balasubramanian BA, et al. Racial differences in the treatment of colorectal cancer: a comparison of surgical and radiation therapy between Whites and Blacks. Ann Epidemiol. 2004; 14: 215-221.
40. Chou C-L, Chang S-C, Lin T-C, et al. Differences in clinicopathological characteristics of colorectal cancer between younger and elderly patients: an analysis of 322 patients from a single institution. Am J Surg. 2011; 202: 574-582.
41. Mitchell ETA, Singla R, et al. Racial disparity trends in clinical presentation and outcomes in colorectal cancer: Findings from an urban university hospital. J Clin Oncol. 2011; 29(suppl 4): 2011, abstr 518.
42. Robbins AS, Siegel RL, Jemal A. Racial disparities in stagespecific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012; 30: 401-405.
43. Obeidat NA, Pradel FG, Zuckerman IH, et al. Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care. 2010; 16: 515-522.
44. Wudel LJ Jr, Chapman WC, Shyr Y, et al. Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival. Arch Surg. 2002; 137: 550-554; discussion 554-556.
45. Agrawal S, Bhupinderjit A, Bhutani MS, et al. Colorectal cancer in African Americans. Am J Gastroenterol. 2005; 100: 515-523; discussion 514.
46. Wang L, Hollenbeak C, Stewart D. Node yield and node involvement in young colon cancer patients: is there a difference in cancer survival based on age? J Gastrointest Surg. 2010; 14: 1355-1361.
47. Singh S, Paraskeva C, Gallimore PH, et al. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res. 1994; 14: 1037-1041.
48. Chan JA, Meyerhardt JA, Chan AT, et al. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol. 2006; 24: 5680-5686.
49. Mandelson MT, Miglioretti D, Newcomb PA, et al. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control. 2003; 14: 979-984.
50. Koo JH, Jalaludin B, Wong SK, et al. Improved survival in young women with colorectal cancer. Am J Gastroenterol. 2008; 103: 1488-1495.
51. Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instabilitypositive colon cancer. Cancer Res. 2001; 61: 126-130.
52. Kang HJ, O'Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005; 48: 1161-1168.
53. Chew MH, Yeo SA, Ng ZP, et al. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2, 764 sporadic colorectal cancers. Int J Colorectal Dis. 2010; 25: 1221-1229.
54. Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012; 19: 2814-2821.
55. Kakar S, Deng G, Smyrk TC, et al. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma. Mod Pathol. 2012; 25: 1040-1047.
56. Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology. 2001; 121: 830-838.
57. Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg. 2000; 87: 1197-1202.
58. Kakar SAS, Smyrk T. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol. 2004; 17: 696-700.
59. Ghazi S, Lindforss U, Lindberg G, et al. Analysis of colorectal cancer morphology in relation to sex, age, location, and family history. J Gastroenterol. 2012; 47: 619-634.
60. Snaebjornsson P, Jonasson L, Jonsson T, et al. Colon cancer in Iceland-a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int J Cancer. 2010; 127: 2645-2653.
61. Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 2008; 23: 418-423.
62. Stillwell AP, Buettner PG, Ho YH. Meta-Analysis of Survival of Patients with Stage IV Colorectal Cancer Managed with Surgical Resection Versus Chemotherapy Alone. World J Surg. 2010; 34: 797-807.
63. Lin J-T, Wang W-S, Yen C-C, et al. Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol. 2005; 20: 900-905.
64. Kam MH, Eu KW, Barben CP, et al. Colorectal cancer in the young: a 12-year review of patients 30 years or less. Colorectal Dis. 2004; 6: 191-194.
65. O'Connell JB, Maggard MA, Livingston EH, et al. Colorectal cancer in the young. Am J Surg. 2004; 187: 343-348.
66. Serra-Rexach JA, Jimenez AB, García-Alhambra MA, et al. Differences in the therapeutic approach to colorectal cancer in young and elderly patients. Oncologist. 2012; 17: 1277-1285.
67. Stillwell A, Ho Y-H, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2011; 35: 684-692.